deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05520619

Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) (EC-CRT-002)

Tislelizumab Plus Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Randomized Trial (EC-CRT-002)

Sponsor: First Affiliated Hospital, Sun Yat-Sen University

Conditions Esophageal Squamous Cell Carcinoma Locally Advanced Esophageal Squamous Cell Carcinoma
Interventions Paclitaxel, Cisplatin Radiotherapy tislelizumab
Updated 7 times since 2022 Last updated: Nov 14, 2024 Started: Sep 15, 2022 Primary completion: Nov 10, 2025 Completion: Jul 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Esophageal Squamous Cell Carcinoma and Locally Advanced Esophageal Squamous Cell Carcinoma, this trial is ongoing. The trial is conducted by First Affiliated Hospital, Sun Yat-Sen University and has accumulated 7 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Dec 2023 · 11 months · monthly snapshotRecruiting~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – present · 19 months · monthly snapshotActive Not Recruiting

Change History

7 versions recorded

  1. Dec 2024 — Present [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Dec 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

  5. Jan 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

▶ Show 2 earlier versions

  1. Nov 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  2. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • First Affiliated Hospital, Sun Yat-Sen University
  • Jieyang People's Hospital
  • Sun Yat-sen University
  • Zhongshan People's Hospital, Guangdong, China
Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations